

Draft

RESOLUTION OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2021 OF DHG PHARMACEUTICAL JSC

THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2021

- Pursuant to the Charter of DHG Pharmaceutical Joint Stock Company (DHG Pharma) issued on 19 Apr 2021;
- Pursuant to the Statements and Reports submitted to the Annual General Meeting of Shareholders (AGM) 2021 on 18 Mar 2022 by the Board of Directors (BOD), the Audit Committee, and the Chief Accountant;
- Pursuant to the Meeting minutes No.003/2022/BB.ĐHĐCĐ of the AGM 2021 of DHG Pharma dated 18 Mar 2022,

RESOLUTION

The AGM 2021 of DHG Pharma unanimously approved the following contents:

Article 1: Approval of the BOD report regarding the Company's performance in 2021, performance and remuneration of the BOD in 2021; Report on the performance of Independent Board Members in the Audit Committee; Audited consolidated financial statements FY 2021.

Several targets in 2021:

No.	Items	Figures in	2021
1.	Total assets as at 31 Dec 2021	VND Billion	4,618
2.	Owner's equity as at 31 Dec 2021	VND Billion	3,793
3.	Net sales	VND Billion	4,003
4.	Profit before tax	VND Billion	864
5.	Profit after tax	VND Billion	776
6.	Profit after tax of the parent company's shareholders	VND Billion	777
7.	EPS (Earnings per share)	VND	5,720
8.	ROS (Profit after tax/Net sales)	%	19.4%
9.	ROA (Profit after tax/Average total assets)	%	17.1%
10.	ROE (Profit after tax/Average owner's equity)	%	21.1%

Article 2: Approval of the business plan for 2022:

- + Net sales: VND 4,220 billion
- + Profit before tax: VND 853 billion

Article 3: Approval of the profit distribution 2021:

Target	Appropriation rate in 2021	Amount (VND)
PAT in 2021 (parent company's shareholders)		777,219,726,033
Dividend payment in 2021	35% of par value	457,611,248,500
Bonus and Welfare Fund	3% of PAT in 2021	23,316,591,781
BOD Remuneration Fund	VND 6 billion	6,000,000,000
The remaining profit shall be added to the Investment & Development Fund	The remaining	290,291,885,752

Article 4: Approval of the profit distribution plan 2022:

Target	Projected appropriation rate 2022
PAT in 2022	100% of PAT
Dividends in 2022	30% of par value (by cash)
Bonus and Welfare Fund	3% of PAT
BOD Remuneration Fund	2,000,000,000
The remaining profit shall be added to the Investment & Development Fund	The remaining

Article 5: Approval of the BOD remuneration in 2022 to be VND 7 billion. In which, VND 5 billion shall be recognized in the Company's expenses and VND 2 billion shall be appropriated from the profit after tax in 2022.

Article 6: Authorizing the BOD/Audit Committee to select one out of four following auditors to audit the financial statements 2022 of DHG Pharma:

- Deloitte Vietnam Company Limited
- Ernst & Young Vietnam Limited
- Price Waterhouse Cooper Vietnam Limited
- KPMG Vietnam Limited

Article 7: Approval of the yearly purchase of directors and officers liability insurance (D&O) by DHG Pharma. The BOD is authorized to carry out the procedures to yearly purchase the directors and officers liability insurance on the basis of compliance with the Company's regulations and current laws.

Article 8: The BOD, General Director and Legal representative of DHG Pharma Term IV (2019 – 2023) have been assigned to implement the contents approved by the AGM in accordance with the Company's Charter and applicable law.

This Resolution is approved by the AGM 2021 of DHG Pharma dated 18 Mar 2022 and is made in 02 (two) original copies of equal legal force.

**ON BEHALF OF THE AGM 2021
CHAIR**

Recipients:

- BOD members, Audit Committee;
- The Company's shareholders;
- SSC; HOSE; VSD HCMC Branch;
- DHG Pharma's website;
- Mass media;
- Archived: BOD Secretary, AT.

DANG THI THU HA

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]